<DOC>
	<DOCNO>NCT00150540</DOCNO>
	<brief_summary>The purpose study assess safety lanthanum carbonate patient undergoing dialysis receive lanthanum carbonate previous study wish continue treatment .</brief_summary>
	<brief_title>A Long Term Study Lanthanum Carbonate Patients Requiring Dialysis Who Have Ived Lanthanum Carbonate Previous Studies Defined Protocol .</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Patients participate LAMIV301 , LAMIV303 , LAMIV307 OR LAMIV308 receive lanthanum carbonate Patients must continue require treatment phosphate binder hyperphosphatemia male nonpregnant female agree use effective contraceptive method study treatment 30 day thereafter Patients withdrawn LAMIV301 , LAMIV303 OR LAMIV307 prior randomization Patients withdraw LAMIV301 , LAMIV303 , LAMIV307 OR LAMIV308 due adverse event term `` possible '' `` relate '' study medication Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2007</verification_date>
</DOC>